Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Sponsors AbbVie

Most Recent Events

  • 24 Jul 2023 According to AbbVie media release, results from this study are planned for publication in a scientific journal. Additional results will be presented at a future medical congress.
  • 21 Mar 2023 Primary endpoint (Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12) has been met, as per results presented at the American Academy of Dermatology annual Meeting 2023.
  • 21 Mar 2023 Results assessing the efficacy and safety of upadacitinib versus placebo in adults with moderate-to-severe hidradenitis suppurativa, presented at the American Academy of Dermatology annual Meeting 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top